6:00pm (EST)
1. Market Summary
2. Solazyme (SZYM) – Worth a Second Look
3. Hologic (HOLX) – Medical Leader Gathering Momentum
4. Earnings
5. Weekly Wrap Portfolio Update
6. Week Ahead
(To view the charts, please log into the Members Area and go to the Weekly Wrap Premium section)
= = = = = = = = = = = = = = =
1. Market Summary
The bulls were able to continue their momentum to start the week as they pushed the market just past resistance after Greece changed governments. Wall Street and the globe then focused on Italy when its debt bonds soared past 7% which lead to a nasty selloff on Wednesday to the tune of 3.5%.
Thursday was a rebound day, as Italy too, decided a changing of the guard would serve the country better. It was out with the old and in with the new Prime Minister which should be named by the time trading starts on Monday. The volatile action left the bulls at a slight disadvantage going into Friday as they were down but not out.
The Dow surged 260 points, or 2.2%, to finish at 12,153. The blue-chips traded to a high of 12,179 before reclaiming the 12,000 level and its 200-day moving average. We mentioned all week the 11,800 (blue line, black circles) level would be crucial in holding with 11,600 providing backup. After testing and holding this area on Wednesday, we told you to stay long and strong. We didn’t think the Dow would clear 12,200 (orange line, green circles) on Friday given the resistance but if it is taken out on the close this week, look for a test up to 12,600-12,800 (black line, purple circles) over the next month or so. The Dow started Monday at 11,983 and added 170 points, or 1.4%, for the week. For the year, the blue-chips are up 576 points, or 5%.
The S&P 500 jumped 23 points, or 2%, to finish at 1,264. The index made a high of 1,267 on Friday and 1,277 on Tuesday. We said coming into the week there could be a test down to 1,225 and on Wednesday the low was 1,226. The trend would change on a break below the 1,200 (green line, black circles) level but we expect a run past 1,275 (blue line, orange circles) and a hold of the 200-day MA this week. If cleared and the bulls can hold, then the momentum could carry the S&P up to 1,300-1,350 (purple line, black circles). The S&P started the week at 1,253 and gained 11 points, or 0.8%, to finish it. With Friday’s close, the index is up 7 points, or 0.5% for 2011.
The Nasdaq popped 54 points, or 2%, to settle at 2,678. Tech traded down to 2,601 on Thursday but was able to hold the 2,600 level (green line, orange circles). There is further risk down to 2,550 if this level is back tested but the bulls will try to push 2,700-2,750 (purple line, black circles) again this week. The one stock that needs to participate in the Nasdaq’s rally to 2,900 (blue line, brown circle) will be Apple (AAPL, $384.62, down $0.60) but that’s another story. Tech lagged the Dow and S&P as it declined 7 points, or 0.3%, for the week after starting Monday’s session at 2,686. For 2011, the Nasaq is still up 26 points, or 1%, for the year.
The S&P Volatility Index (^VIX, 30.04, down 2.77) went on a wild ride after starting the week just above 30 (orange line, purple circles). The VIX traded to a high of 36.43 during Wednesday’s selloff but lower than the prior week’s high of 37.53. Remember, a break above 40 (blue line, green circles) would be bearish but we have been telling you the VIX could trade down to 22.5 (green line, black circles) if the bulls can push the July highs.
We mentioned Apple’s weakness earlier and last week we talked about a possible push to $60 (black line, green circles) for the PowerShares QQQ Trust (QQQ, $57.85, up $1.07).
If Apple can clear $400 and the Q’s can power past $60, we can add two more check marks for a continued rally.
Although Europe has caused some extreme volatility, we used our support and resistance targets to remain calm. It may be hard sometimes to buy call options when the market is selling off or buy put options when the market is rallying. However, if you can keep your head straight and block out the talking heads then it’s easy to stick to your game plan and follow the trend.
Greece and Italy seem to have headline breaking news, daily, and we doubt this changes any time soon. In fact, don’t be surprised if France gets thrown in the mix along with reoccurring rhetoric about Portugal, Ireland, and Spain at some point. Did we leave anyone out?
The clues we gave you in October that this market is going higher are playing out like spades. The charts have proven to be spot on but we get a little worried when the talking heads and their guests start to get giddy. On Wednesday, we couldn’t find anyone who agreed with our bullish stance as most of the same knuckleheads were calling for the market to fall off a cliff following Wednesday’s 3% drubbing.
We backed our conviction up by going long two more call trades for our Daily on Wednesday but it doesn’t mean we aren’t nervous. The bulls still have to have a lot of things go right.
= = = = = = = = = = = = = = =
2. Solazyme (SZYM) – Worth a Second Look
Solazyme (SZYM, $11.33, up $0.86) has for the most part been a terrible investment but is it time to look again at the company, given its surge this past week?
The $675 million company based in San Francisco went public in late May, selling about 11 million shares at $18 each. The stock ran up to $27.47 on July 12th but sank to a low of $7.68 on October 13th. Shares surged 17% Thursday following its earnings release but more importantly the announcement of its current contracts.
The company is not profitable, having reported a wider loss in the 3rd quarter. Revenue came in at $8.9 million, up from $7.4 million in the 2nd quarter and $4.6 million a year earlier. Non-GAAP loss was $11.5 million, or $0.19, for the 3rd quarter ending on September 30th. GAAP loss was $14.1 million, or $0.24. The average analysts’ estimate was for GAAP loss of $0.22 on revenue of $10.4 million. Thus, both earnings and revenue missed analysts’ expectations. The graphs below show the trend in earnings and revenue and include estimates for the 4th quarter (12/11). Analysts predict that earnings and revenue will come at -$0.16 on $15.04 million.
The good thing is that both revenue and earnings seem to be growing, but as for revenue, we would like to see more growth. We may get that as analysts seem to expect revenue and earnings will see another spike like last year.
Source: Google Finance
The company’s cash reserve has grown to about $251 million or about 37% of its market capital. The graphs above show cash flow from financing is growing healthily. Total assets have surged in recent years while debt has remained low at just over $20 million. However, net income and profit margin have been falling in recent quarters.
Using patented microalgae, Solazyme turns sugarcane, grass, and plant sugars into oils. It then distributes the processed oils among four divisions: fuels, chemicals, nutritionals, and health sciences. In the fuels segment, it has partnered with Honeywell International (HON, $54.79, up $1.23) to processes its oils into fuel. It has partnered with Unilever (UN, $33.93, up $0.83) and Dow Chemical (DOW, $28.19, up $0.78) to crack into the estimated $600 billion petrochemicals market. It has partnered with Roquette Frères to launch Solazyme-Roquette Nutritionals, a joint venture commercializing an array of microalgae-derived food ingredients. And the Health Sciences business is targeting the global skin and personal care market, which is estimated at over $300 billion.
Solazyme has secured 90% of its feedstock manufacturing capacity through 2015. In addition, it is testing Solajet with the U.S. armed forces in which the fuel was successfully used in a patrol craft. Phase two of the Navy contract is fully funded. Even better and most impressive of all is United Airlines recently did a commercial flight using a blend of its algae-derived renewable jet fuel to successfully fly from Houston to Chicago using a 40% blend of Solajet. As a result, United Continental (UAL, $18.02, up $0.70) agreed to purchase up to 20 million gallons per year of renewable jet fuel starting in 2014.
Considering that jet fuel currently sells for $3.119 a gallon that is about $62.38 million per year. Thus, just the cash and the $62.38 million is almost 50% of the companies market capital. If it can get six more $62 million contracts, it will have enough cash to pay its entire market capital. And considering that its price/book is a reasonable 2.47, and its current ratio is a whopping 14.49, the stock seems worth the risks.
At $11.33, the stock is near its low target of $12.50 made by the 7 analysts recorded by Thomson/First Call. Mean target is $21.79, median target is $22.00, and high target is $29.00. Using a scale of 1.0 as a strong buy and 5.0 as a sell, the average rating of the stock was 1.7, unchanged from a week ago.
|
|
Current Month |
Last Month |
Two Months Ago |
Three Months Ago |
|
Strong Buy |
2 |
2 |
3 |
2 |
|
Buy |
5 |
5 |
4 |
4 |
|
Hold |
0 |
0 |
0 |
0 |
|
Underperform |
0 |
0 |
0 |
0 |
|
Sell |
0 |
0 |
0 |
0 |
One analyst has an “outperform” rating on the stock with a price target of $34.
Taking a positive view on the stock and an ascent of $0.056 per day, it will take the stock 34 days to reach $15.
= = = = = = = = = = = = = = =
3. Hologic (HOLX) – Medical Leader Gathering Momentum
Hologic (HOLX, $17.77, up $0.68) reported strong earnings and just may be ripe for a breakout. The company is a leading provider of medical imaging and women’s healthcare and has a generally strong business. However, there seems to be little growth at home and in Europe, which is considered mature. Thus, pushing into more growing markets overseas is crucial to the company’s growth plan. And if successful, the stock may surge.
The company operates in four segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment offers breast imaging products, breast biopsy, CAD, and mammography systems. The Diagnostics segment provides solutions for cervical cancer screening as well as pre-term birth risk assessment. The GYN Surgical segment offers treatment for women suffering from excessive menstrual bleeding. The Skeletal Health segment assesses and measures bone density.
The number of 2D and 3D imaging systems sold continues to increase quarterly and represents an increasing proportion of total mammography revenue (57% in 3rd quarter, up from 47% and 37% in the 2nd and 3rd quarters, respectively). Sales of the 3D system, in its initial stages in the US, are expected to ramp up gradually. However, significant sales growth is not expected to begin before mid-2012.
The company just reported 4th quarter earnings, beating analysts’ expectations with net income of $27.6 million, compared with a net loss of $137.0 million during the same quarter in 2010. Revenue rose to $467.0 million, up 9% year-over-year. Revenue grew in all four of its business sections. Analysts predict that earnings and revenue will come at $0.32 on $466.90 million in the 1st quarter (12/11). In the 2nd quarter (3/12), analysts are looking for earnings and revenue of $0.33 on $470.72 million. Estimates are included in graphs below.
Analysts seem to expect that revenue and earnings will start to rapidly slow or fall, which seems unlikely. In our view, the company seems a little undervalued compared to its peers and its industry.
BCR = C.R. Bard BDX = Becton, Dickenson and Company GPRO = Gen-Probe
QGEN = Qiagen NV Industry = Medical Appliances & Equipment
|
|
HOLX |
BCR |
BDX |
GPRO |
QGEN |
Industry |
|
Price/Sales |
2.56 |
2.62 |
2.04 |
5.05 |
2.95 |
2.17 |
|
Price/Book |
1.54 |
4.06 |
3.02 |
3.64 |
1.30 |
— |
|
Trailing PE |
— |
22.86 |
13.20 |
52.40 |
26.40 |
22.09 |
|
Forward PE |
11.85 |
12.73 |
11.53 |
23.00 |
14.24 |
— |
|
PEG |
1.36 |
1.30 |
1.34 |
2.15 |
1.38 |
1.18 |
|
Revenue Growth (%) |
7.20 |
6.00 |
18.40 |
4.90 |
5.30 |
16.60 |
|
Gross Margin (%) |
62.43 |
62.30 |
52.26 |
70.80 |
65.99 |
56.26 |
|
Total Debt/Revenue |
0.840 |
0.318 |
0.347 |
0.447 |
0.713 |
— |
|
Cash Flow/Revenue |
0.261 |
0.253 |
0.223 |
0.310 |
0.224 |
— |
|
Current Ratio |
2.59 |
3.75 |
2.70 |
1.55 |
1.50 |
— |
|
Market Cap/Revenue |
2.663 |
2.668 |
2.059 |
5.174 |
3.036 |
1.746 |
|
Market Cap/Cash |
7.592 |
9.948 |
8.352 |
9.491 |
6.991 |
— |
|
EV/Revenue |
3.15 |
2.71 |
2.16 |
5.08 |
3.31 |
— |
|
EV/EBITDA |
9.17 |
8.43 |
7.49 |
15.45 |
10.61 |
— |
|
Return on Assets (%) |
3.24 |
12.25 |
16.24 |
10.37 |
3.10 |
— |
|
Return on Equity (%) |
-0.26 |
28.29 |
22.57 |
24.68 |
5.27 |
— |
|
Total Debt/Equity |
50.53 |
49.16 |
51.43 |
32.26 |
30.88 |
— |
|
Short Ratio |
2.40 |
1.70 |
4.40 |
3.20 |
2.90 |
— |
|
Short Interest (%) |
2.087 |
2.098 |
2.874 |
2.013 |
2.606 |
— |
|
Short Change (%) |
-0.080 |
-0.140 |
0.184 |
-0.118 |
-0.547 |
— |
Source: Numbers calculated from Yahoo Finance
On the negative side, Hologic has a lot of debt compared to competitors. The size of its debt is 0.84 times its revenue, a potential red flag. The other big red flag is that its return on equity is negative, while all of its top competitors have a positive return on equity. The positives are that it has one of the lowest price/sales, price/book, and forward PE’s in the group and has enough current assets to cover current liabilities, meaning short-term credit seems intact.
At $17.77, the stock is near its low target of $17.00 made by the 18 analysts recorded by Thomson/First Call. Mean target is $22, median target is $21.50 and high target is $26.00. Using a scale of 1.0 as a strong buy and 5.0 as a sell, the average rating of the stock was 1.8, unchanged from a week ago.
|
|
Current Month |
Last Month |
Two Months Ago |
Three Months Ago |
|
Strong Buy |
10 |
9 |
10 |
9 |
|
Buy |
9 |
9 |
8 |
8 |
|
Hold |
5 |
5 |
5 |
6 |
|
Underperform |
0 |
0 |
1 |
2 |
|
Sell |
0 |
0 |
0 |
0 |
Here is the shorter-term chart:
We have been following Hologic for about 6 months and although we haven’t made any official recommendations on the stock, we feel shares can reach $25 in 2012 if all goes well.
= = = = = = = = = = = = = = =
4. Earnings
The companies in BOLD, we are looking at as possible trades and we may list call or put options on them in our Daily Newsletter. If they become official recommendations, we sent out Trade Alerts or include them in our 9am and 1pm updates that come out during the week (Quotes are as of Friday’s close, 11/11/11).
MONDAY
Advanced Battery Technologies (ABAT, $1.02, down $0.02), Brigham Exploration (BEXP, $36.38, down $0.04), Craft Brewers Alliance (HOOK, $6.47, up $0.23), Crumbs Bake Shop (CRMB, $4.94, down $0.08), Elong (LONG, $12.50, up $0.30), Emerson Radio (MSN, $1.62, up $0.02), Global Power Equipment Group (GLPW, $27.75, up $1.26), InterOil (IOC, $50.45, up $1.61), J C Penney (JCP, $33.92, up $1.02), Limited Brands (LTD, $43.94, up $1.63), Lowes Companies (LOW, $23.11, up $0.65), Scorpio Tankers (STNG, $6.85, up $1.02), Sky-mobi (MOBI, $4.94, up $0.01), Station Casinos (STN, $24.97, up $0.54), Zagg (ZAGG, $11.78, up $0.86)
TUESDAY
Agilent Technologies (A, $37.46, up $0.60), Autodesk (ADSK, $34.20, up $1.48), Beazer Homes USA (BZH, $2.40, up $0.18), Bob Evans Farms (BOBE, $33.63, up $0.44), Dell (DELL, $15.35, up $0.39), Dicks Sporting Goods (DKS, $39.99, up $1.28), First Bancshares (FBSI, $4.83, down $0.24), Home Depot (HD, $38.06, up $0.86), Jacobs Engineering Group (JEC, $38.96, up $1.07), Saks (SKS, $10.18, up $0.16), Staples (SPLS, $15.43, up $0.89), TJX Companies (TJX, $61.34, up $1.35), Wal-Mart Stores (WMT, $59.20, up $1.07)
WEDNESDAY
Abercrombie & Fitch (ANF, $56.80, up $1.34), Dole Food (DOLE, $10.67, up $0.33), Fortune Industries (FFI, $0.52, Flat), Hot Topic (HOTT, $6.95, up $0.18), InterGroup (INTG, $19.74, up $0.54), Magnetek (MAG, $0.93, Flat), NetApp (NTAP, $42.17, up $0.28), NetEase.com (NTES, $44.59, up $0.79), PetSmart (PETM, $48.15, up $1.53), Target (TGT, $53.07, up $1.30), Tyco International (TYC, $46.12, up $1.51), Zoll Medical (ZOLL, $36.65, up $1.88)
THURSDAY
Aruba Networks (ARUN, $23.44, up $0.40), Blue Coat Systems (BCSI, $15.86, up $0.85), Books A Million (BAMM, $2.66, down $0.20), Cato (CATO, $26.86, up $1.31), Children’s Place Retail Stores (PLCE, $47.22, up $0.72), Dolby Laboratories (DLB, $28.78, down $0.07), Dollar Tree (DLTR, $78.67, up $0.80), Foot Locker (FL, $23.22, up $1.04), GameStop (GME, $25.17, up $0.57), Gap (GPS, $20.33, up $0.65), Intuit (INTU, $54.02, up $1.22), Kingstone Companies (KINS, $3.20, Flat), Marshall Edwards (MSHL, $1.30, up $0.01), Ross Stores (ROST, $89.77, up $1.70), Salesforce.com (CRM, $129.87, up $2.06), Sears Holdings (SHLD, $74.34, up $1.54), Stein Mart (SMRT, $6.54, Flat), Wet Seal (WTSLA, $3.29, up $0.11), Zoom Technologies (ZOOM, $1.64, down $0.07),
FRIDAY
Ann (ANN, $25.94, up $0.92), Benihana (BNHN, $9.25, Flat), Brady (BRC, $30.73, up $0.67), Hibbett Sports (HIBB, $44.13, up $1.69), Recon Technology (RCON, $0.72, Flat), Sirona Dental Systems (SIRO, $43.35, down $1.13), Tsakos Energy Navigation (TNP, $6.20, up $0.12), WGL Holdings (WGL, $43.31, up $0.97)
= = = = = = = = = = = = = = =
5. Weekly Wrap Covered Call Portfolio Update (Closing prices as of 11/11/11)
WEEKLY WRAP CLOSED TRADES for 2011 (12-0): F + 7%, RMBS +16%, SYMC +4%, VVUS +18%, DNDN +9%, PCX +13%, SGEN +26%, TIVO +34%, REDF +11%, PCX +7%, GE +5%, CLNE +13%
Dendreon (DNDN, $7.21, down $0.06)
November 10 calls (DNDN111119C00010000, $0.05, flat)
Original Entry Price: $9.95 (10/26/11)
Lowered Price from Selling Options: $8.85
Exit Target: $10+
Return: -19%
Stop Target: None
Action: Shares traded to a high of $7.55 last week and short-term resistance is at $7.50 (orange line, purple circles). The low was $6.48 to start the week and there is further risk down to $5 (black line, green circles) if shares do not form a base at current levels. The good news is the options premiums are still fat and we will look to sell a December or January call once these expire on Friday. Also, with shares this low, there could be a buyout offer down the road.
We recommended buying the stock at $9.95 on 10/26/11 and for every 100 shares to sell the November calls for $1. This lowered the cost basis to $8.85.
If shares are called-away by mid-November at $10 the trade makes 12%.
Vivus (VVUS, $9.92, up $0.29)
November 9 calls (VVUS111119C00009000, $0.95, up $0.20)
Original Entry Price: $8.45 (9/9/11)
Lowered Price from Selling Options: $7.70
Exit Target: $10+
Return: 29%
Stop Target: None
Action: Vivus ended the week where it started despite reporting better-than-expected earnings (losses). We will likely get exercised on these options as long as support at $9 (orange line, green circles) holds. We still feel a run to $11.50-$12 (purple line, brown circles) is in the cards and possibly blue-sky territory if they get their diet drug, Qnexa, approved. We have also recommended VVUS call options in our Daily publication.
We recommended buying the stock at $8.45 on 9/9/11 and for every 100 shares to sell the October 9 calls for 40 cents. This lowered the cost basis to $8.05.
On 10/26/11 we recommended selling the November 9 call option for $0.35 which lowered the cost basis to $7.70.
If shares are called-away by mid-November at $9 the trade makes 17%.
MGM Resorts (MGM, $10.30, up $0.36)
November 11 calls (MGM111119C00010000, $0.08, up $0.02)
Original Entry Price: $11.73 (8/12/11)
Lowered Price from Selling Options: $9.73
Exit Target: $12+
Return: 6%
Stop Target: None
Action: Shares broke below $11 and under the second wave of support at $10 (black line, green circles) before jumping 4% on Friday. There is further risk down to $9 (blue line, brown circles) but we feel current levels will hold. There is a chance we get called-away at $11 (orange line, purple circles), but if not, we will look to sell a December of January call next week.
We recommended buying the stock at $11.73 on 8/12/11 and for every 100 shares to sell the September 12 calls for 90 cents. This lowered the cost basis to $10.83.
On 9/20/11 we recommended selling the October 12 call option for $0.60 which lowered the cost basis to $10.23.
On 10/26/11 we recommended selling the November 11 call option for $0.50 which lowered the cost basis to $9.73.
If shares are called-away by mid-November at $11 the trade makes 13%.
Newpark Resources (NR, $9.13, up $0.10)
December 10 call (NR111217C00010000, $0.70, flat)
Original Entry Price: $9.45 (7/27/11)
Lowered Price from Selling Options: $8.10
Exit Target: $10+
Return: 13%
Stop Target: None
Action: Newpark fell 30 cents for the week. Shares were able to hold the $9 level and backup support is strong at $8 (orange line, black circles). The $9.50-$10 (blue line, green circles) level represents resistance and multi-year highs.
We recommended buying the stock at $9.45 on 7/27/11 and for every 100 shares to sell the August 10 calls for 50 cents. This lowered the cost basis to $8.95.
On 9/15/11 we recommended selling the December 10 call option for $0.85 which lowered the cost basis to $8.10.
If we are called away at $10 in mid-December, the trade makes 23%.
Rare Element Resources (REE, $6.67, down $0.32)
Original Entry Price: $12.38 (5/31/11)
Lowered Price from Selling Options: $11.23
Exit Target: $15+
Return: -41%
Stop Target: None
Action: Shares traded to a high of $7.50 last week and the $8 (purple line, orange circles) level represents the next wave of resistance. However, shares were weak on Friday after Molycorp (MCP, $33.45, down $5.25) missed Wall Street’s expectations. Support is at $6 (green line, black circles) if current levels don’t hold up.
We recommended buying the stock at $12.38 on 5/31/11 and for every 100 shares to sell the July 12 calls for $1.15. This lowered the cost basis to $11.23.
AKS Steel Holding (AKS, $9.04, up $0.49)
Original Entry Price: $15.93 (5/2/11)
Lowered Price from Selling Options (and dividends): $14.43
Exit Target: $20+
Return: -37%
Stop Target: None
Action: The company paid a 5 dividend last week and is trying to break through resistance at $9 (black line, green circles). Shares dipped to a low of $8.49 last Wednesday and there is further support at $8 (orange line, brown circles). If shares can hold $9 there is a chance for a run to $11 (blue line, purple circle) which is where we will look to sell another call option.
We recommended buying the stock at $15.93 on 5/2/11 and for every 100 shares to sell the May 16 calls for 50 cents. This lowered the cost basis to $15.43.
On 5/11/11 the company paid out a 5 cent quarterly dividend. This lowered the cost basis to $15.38.
On 7/1/11 we recommended selling the August 16 call option for $0.85 which lowered the cost basis to $14.53.
On 8/11/11 the company paid out a 5 cent quarterly dividend. This lowered the cost basis to $14.48.
On 11/10/11 the company paid out a 5 cent quarterly dividend. This lowered the cost basis to $14.43.
American Capital (ACAS, $7.49, up $0.12)
Original Entry Price: $9.73 (4/19/11)
Lowered Price from Selling Options: $8.38
Exit Target: $15+
Return: -11%
Stop Target: None
Action: American Capital fell below the $7.50 level and tested support at $7 (orange line, black circle) on Wednesday’s market plunge. Once shares can reclaim $8.50-$9 (purple line, green circles) we will write another call option.
We recommended buying the stock at $9.73 on 4/19/11 and for every 100 shares to sell the June 10 call for 50 cents. This lowered the cost basis to $9.23.
On 7/1/11 we recommended selling the August 10 call option for $0.55 which lowered the cost basis to $8.68.
On 9/13/11 we recommended selling the October 9 call option for $0.30 which lowered the cost basis to $8.38.
Cisco Systems (CSCO, $19.02, up $0.41)
November 17 calls (CSCO111119C00017000, $2.05, up $0.40)
Original Entry Price: $17.14 (3/17/11)
Lowered Price from Selling Options (and dividends): $15.51
Exit Target: $20+
Return: 23%
Stop Target: None
Action: Cisco will probably get called-away on Friday unless something major happens. Shares made a run past resistance at $19 (black line, green circles) on Thursday after beating Wall Street’s earnings expectations and should challenge $20-$21 (purple line, brown circles) over the next few weeks. We only need $17 (blue line, orange circles) to hold this week to get exercised.
We recommended buying the stock at $17.14 on 3/17/11 and for every 100 shares to sell the May 18 call for 56 cents. This lowered the cost basis to $16.58.
On 7/5/11 the company paid out a 6 cent quarterly dividend. This lowered the cost basis to $16.52.
On 7/22/11 we recommended selling the August 17 calls for 30 cents which lowered the cost basis to $16.22.
On 9/9/11 we recommended selling the November 17 calls for 65 cents which lowered the cost basis to $15.57.
On 10/4/11 the company paid out a 6 cent quarterly dividend. This lowered the cost basis to $15.51.
If shares are above $17 by mid-November and we are called away, the trade makes 9%.
Spreadtrum Communications (SPRD, $28.71, up $2.14)
November 25 call (SPRD111119C00025000, $3.70, up $1.55)
Entry Price: $23.45 (2/7/11)
Lowered Price from Selling Options (and dividends): $20.38
Exit Target: $30
Return: 41%
Stop Target: None
Action: Spreadtrum beat analyst’s estimates by 16 cents after they announced earnings…16 cents (!), but the stock got no Wall Street loving. Shares traded to a low of $25.50 on Thursday after opening at $27.62. However, the rebound on Friday was nice to see and support is strong at $24 followed by $22 (black line, green circles). We are looking for a test past $30 (blue line) and may get back into Spreadtrum if the stock is called-away.
Shares opened at $23.43 on 2/7/11 and the March calls could have been sold for 95 cents. This lowered the cost basis to $22.48.
On 4/11/11 we recommended selling the May 22.50 call option for $1.00 which lowered the cost basis to $21.48.
On 7/7/11 the company paid out a 5 cent quarterly dividend. This lowered the cost basis to $21.43.
On 9/15/11 we recommended selling the November 25 call option for $1 which lowered the cost basis to $20.43. If we are called away, the trade makes 22%.
On 10/6/11 the company paid out a 5 cent quarterly dividend. This lowered the cost basis to $20.38.
If we are called-away in mid-November at $25 the trade will make 23%.
DryShips (DRYS, $2.88. up $0.05)
January 2012 7.50 call (DRYS120121C00007500, $0.02, flat)
Entry Price: $5.25 (1/03/11)
Lowered Price from Selling Options: $4.60
Exit Target: $8
Return: -37%
Stop Target: None
Action: DryShips continues to battle resistance at $3 (green line, black circles) while support at $2.50 (purple line, blue circles) is holding up well.
DryShips opened at $5.37 on 1/3/11 and shares were at $5.25 shortly after the bell. The January call options could have been sold for 65 cents which lowered the cost basis to $4.60.
If shares are over $7.50 by January 2012, the stock will be “called away” and the trade will make over 60%.
= = = = = = = = = = = = = = =
6. Week Ahead
Economic news has been coming in better-than-expected in most cases and the jobs numbers continue to be encouraging but there are no major reports due out on Monday,
For Tuesday, the morning starts off with inflation data as the Producer Price Index (PPI) and Core PPI numbers will be released an hour before the open. Also, Retail Sales and the Empire State Manufacturing reports are due out at the same time. Business Inventories will be announced 30 minutes after the start of trading.
Wednesday’s session kicks off with the MBA Mortgage Index at 7am (EST). The Consumer Price Index (CPI) and Core CPI figures are due out at 8:30am. Industrial Production and the Capacity Utilization numbers will be released at 9:15am. After the opening bell, the NAHB Housing Market Index will be announced followed by the weekly crude inventory report.
On Thursday, we start the morning with Initial Claims and Continuing Claims along with Housing Starts and Building Permits at 8:30am. The Philly Fed is due out 30 minutes after the open and will be a market mover.
Friday wraps up with the Conference Board’s index of Leading Indicators. However, the big news for the day will come from overseas as we get an update on Germany’s inflation numbers.





















